Liver Cancer Therapeutics Market Size 2021 | Is expected to reach USD 7,382.1 million by 2027, registering a CAGR of 20.2%
Key Prominent Players Covered in the Liver Cancer Therapeutics Market Research Report Are Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany) , Bristol-Myers & Squibb Company (New York, U.S) , Pfizer Inc. (New York, U.S) , Exelixis, Inc. (California, U.S) , Merck Sharp & Dohme Corp. (New jersey, U.S) , Eisai Inc. (Tokyo, Japan) , Eli Lilly and Company (Indiana, U.S) , F. Hoffmann-La Roche Ltd (Basel, Switzerland) , Other PlayersPune, India, March 31, 2021 (GLOBE NEWSWIRE) — The global “liver cancer therapeutics“ market size is expected to reach USD 7,382.1 million by 2027, registering a CAGR of 20.2% during the forecast period. The emergence of effective drugs and therapies for the treatment of liver cancer will subsequently spur lucrative opportunities for the market, states Fortune Business Insights, in a report, titled “Liver Cancer Therapeutics Market Size, Share & Industry Analysis, By Therapy Type (Targeted Drug Therapy, Immunotherapy, and Chemotherapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027.” The market size stood at USD 1,730.9 million in 2019. The coronavirus incident has brought the world to an unprecedented stop. We understand that this health crisis has brought an unwonted effect on businesses across various. However, this too, shall pass. Rising support from governments and several companies can help in the fight against this highly infectious virus. There are some industries that are struggling, and some are thriving. More or less, nearly every sector is estimated to be impacted by this pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/sample/liver-cancer-therapeutics-market-104657 Key Development: November 2020: Exelixis, a genomics-based drug discovery company, located in Alameda, California, announced the approval of CABOMETYX in Japan for the treatment of unresectable hepatocellular carcinoma. An Overview of the Impact of COVID-19 on this Market: The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic. We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future. For More Information in the Analysis of Reports: https://www.fortunebusinessinsights.com/liver-cancer-therapeutics-market-104657 The report on the liver cancer therapeutics market, specifically mentions minute and significant improvements in the global market in recent times. The report also offers a wide-ranging study fixated on emerging trends and new innovative products. The robust research methodology involving primary interviews and desk research is covered in the report while also providing a noteworthy overview of the R&D activities and latest developments to support emerging companies to strengthen their position and strategize to remain at the forefront. Rising Cases of Liver Cancer to Boost Market The increasing incidence of liver cancer is expected to expedite the growth of the market during the forecast period. Alcohol & tobacco consumption, smoking, and environmental factors in developed nations are some of the reasons for the prevalence of cancer. The increasing urbanization is expected to bolster the healthy growth of the market in the forthcoming years. According to the World Cancer Research Fund, in 2018, there were around 840 000 new cases of liver cancer. Moreover, the growing demand for effective drugs is predicted further to boost the market’s development in the foreseeable future. However, oncology drugs’ adverse side effects will consequently restrict their adoption, which will retard the growth of the market. Favorable Guidelines and Recommendations for Cancer Drugs to Aid Market Amid COVID The pharmaceutical companies are adopting strategies to maintain the balance between supply and demand. Health organizations have issued necessary guidelines and recommendations for managing hepatocellular carcinoma patients in the time coronavirus. For instance, the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), National Institute of Health and Care Excellence (NICE) have proposed guidelines. Furthermore, several research studies have confirmed that patients with HCC are at higher risk of contracting the infection. Therefore, these patients were considered in the emergency category during the pandemic. Besides, the increased sales of cancer products will foster healthy growth of the market amid COVID-19. Quick Buy – Liver Cancer Therapeutics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/104657 Presence of Prominent Companies to Incite Growth in North America The market in North America is expected to expand radically during the forecast period owing to the rising incidence of liver cancer in the US. The presence of major companies, coupled with the launch of novel products will influence growth in the region. Europe is expected to expand radically during the forecast period due to the R&D investments to develop effective drugs. The higher sales of targeted drug therapy products is expected to boost the growth of the market in Europe. Asia Pacific is expected to rise excellently during the forecast period owing to the growing number of clinical studies pertaining to liver cancer. The increasing geriatric population is likely to contribute impetus in the region. Latin America, and Middle East & Africa are likely to experience a slower growth rate owing to lower adoption of high-cost liver cancer drugs. Similarly, the lack of product approvals in the majority of the under-developed countries can further dampen the growth of the market in those regions. The Report Lists the Key Companies in the Liver Cancer Therapeutics Market: Bayer HealthCare Pharmaceuticals Inc. (Leverkusen, Germany)Bristol-Myers & Squibb Company (New York, U.S)Pfizer Inc. (New York, U.S)Exelixis, Inc. (California, U.S)Merck Sharp & Dohme Corp. (New jersey, U.S)Eisai Inc. (Tokyo, Japan)Eli Lilly and Company (Indiana, U.S)F. Hoffmann-La Roche Ltd (Basel, Switzerland)Other Players Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/liver-cancer-therapeutics-market-104657 Table Of Content: Introduction Market ScopeMarket SegmentationMarket MethodologyDefinitions and Assumptions Executive SummaryMarket Dynamics Market DriversMarket RestraintsMarket Opportunities Key Insights Prevalence of Liver Cancer –Key Regions/CountryNew Product Launch Pipeline AnalysisImpact of COVID-19 on the Liver Cancer Treatment MarketKey Industry Developments – Mergers, Acquisitions, and Partnerships Global Liver Cancer Treatment Market Analysis, Insights and Forecast, 2016-2027 Key Findings / SummaryMarket Analysis, Insights and Forecast – By Therapy Targeted Drug Therapy Immunotherapy Chemotherapy Market Analysis, Insights and Forecast – By Distribution Channel Hospital Pharmacy Retail Pharmacy Online Pharmacy Market Analysis, Insights and Forecast – By Geography North America Europe Asia Pacific Latin America Middle East & Africa ToC Continue… Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/liver-cancer-therapeutics-market-104657 SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION: Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline. Have a Look at Related Reports: Medical X-ray Market Size, Share & Covid-19 Impact Analysis, By Product Type (Static and Dynamic), By Technology Type (Analog and Digital), By Application (Dental, Veterinary, Cardiovascular Oncology, and Others), By End-User (Hospitals & Clinics, Diagnostic Centers, and Others), and Regional Forecast, 2021-2028 North America Osteoporosis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator (SERMs), RANK ligand (RANKL) Inhibitor, and Others), By Route of Administration (Oral, and Parenteral); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies) and Forecast, 2020-2027 Point of care Ultrasound Market Size, Share & COVID-19 Impact Analysis, By Product (Cart-based, and Hand-held), By End User (Hospitals, Clinics, and Others), and Regional Forecast, 2020-2026 Immunomodulators Market Size, Share & COVID-19 Impact Analysis, By Product Type (Immunosuppressant, Immunostimulants), By Application (Oncology, Respiratory, Multiple Sclerosis, and Others), and Regional Forecast, 2020-2027 Immune Thrombocytopenia (ITP) Market Share & Industry Analysis, By Type (Acute Immune Thrombocytopenia, and Chronic Immune thrombocytopenia), By Treatment (Thrombopoietin Receptor Agonist, Immunoglobulins, Corticosteroids, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) and Regional Forecast, 2019-2026 About Us: Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us: Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune – 411045, Maharashtra, India. Phone:US :+1 424 253 0390UK : +44 2071 939123APAC : +91 744 740 1245Email: firstname.lastname@example.orgFortune Business Insights™LinkedIn | Twitter | Blogs Press Release: https://www.fortunebusinessinsights.com/press-release/global-liver-cancer-therapeutics-market-10450
CANADA STOCKS – TSX ends flat at 19,228.03
* The Toronto Stock Exchange’s TSX falls 0.00 percent to 19,228.03
* Leading the index were Corus Entertainment Inc <CJRb.TO>, up 7.0%, Methanex Corp, up 6.4%, and Canaccord Genuity Group Inc, higher by 5.5%.
* Lagging shares were Denison Mines Corp, down 7.0%, Trillium Therapeutics Inc, down 7.0%, and Nexgen Energy Ltd, lower by 5.7%.
* On the TSX 93 issues rose and 128 fell as a 0.7-to-1 ratio favored decliners. There were 26 new highs and no new lows, with total volume of 183.7 million shares.
* The most heavily traded shares by volume were Toronto-dominion Bank, Nutrien Ltd and Organigram Holdings Inc.
* The TSX’s energy group fell 1.61 points, or 1.4%, while the financials sector climbed 0.67 points, or 0.2%.
* West Texas Intermediate crude futures fell 0.44%, or $0.26, to $59.34 a barrel. Brent crude fell 0.24%, or $0.15, to $63.05 [O/R]
* The TSX is up 10.3% for the year.
Canadian dollar outshines G10 peers, boosted by jobs surge
By Fergal Smith
TORONTO (Reuters) – The Canadian dollar advanced against its broadly stronger U.S. counterpart on Friday as data showing the economy added far more jobs than expected in March offset lower oil prices, with the loonie also gaining for the week.
Canada added 303,100 jobs in March, triple analyst expectations, driven by the recovery across sectors hit by shutdowns in December and January to curb the new coronavirus.
“The Canadian economy keeps beating expectations,” said Michael Goshko, corporate risk manager at Western Union Business Solutions. “It seems like the economy is adapting to these closures and restrictions.”
Stronger-than-expected economic growth could pull forward the timing of the first interest rate hike by the Bank of Canada, Goshko said.
The central bank has signaled that its benchmark rate will stay at a record low of 0.25% until 2023. It is due to update its economic forecasts on April 21, when some analysts expect it to cut bond purchases.
The Canadian dollar was trading 0.3% higher at 1.2530 to the greenback, or 79.81 U.S. cents, the biggest gain among G10 currencies. For the week, it was also up 0.3%.
Still, speculators have cut their bullish bets on the Canadian dollar to the lowest since December, data from the U.S. Commodity Futures Trading Commission showed. As of April 6, net long positions had fallen to 2,690 contracts from 6,518 in the prior week.
The price of oil, one of Canada‘s major exports, was pressured by rising supplies from major producers. U.S. crude prices settled 0.5% lower at $59.32 a barrel, while the U.S. dollar gained ground against a basket of major currencies, supported by higher U.S. Treasury yields.
Canadian government bond yields also climbed and the curve steepened, with the 10-year up 4.1 basis points at 1.502%.
(Reporting by Fergal Smith; Editing by Andrea Ricci)
Canadian dollar rebounds from one-week low ahead of jobs data
By Fergal Smith
TORONTO (Reuters) -The Canadian dollar strengthened against its U.S. counterpart on Thursday, recovering from a one-week low the day before, as the level of oil prices bolstered the medium-term outlook for the currency and ahead of domestic jobs data on Friday.
The Canadian dollar was trading 0.4% higher at 1.2560 to the greenback, or 79.62 U.S. cents. On Wednesday, it touched its weakest intraday level since March 31 at 1.2634.
“We have seen partial retracement from the decline over the last couple of days,” said Greg Anderson, global head of foreign exchange strategy at BMO Capital Markets.
“With oil prices where they are – let’s call WCS still at roughly $49 a barrel – I still think CAD has room to strengthen over the medium term and even over a one-week horizon.”
Western Canadian Select (WCS), the heavy blend of oil that Canada produces, trades at a discount to the U.S. benchmark. U.S. crude futures settled 0.3% lower at $59.60 a barrel, but were up nearly 80% since last November.
The S&P 500 closed at a record high as Treasury yields fell following softer-than-anticipated labor market data, while the U.S. dollar fell to a two-week low against a basket of major currencies.
Canada‘s employment report for March, due on Friday, could offer clues on the Bank of Canada‘s policy outlook. The central bank has become more upbeat about prospects for economic growth, while some strategists expect it to cut bond purchases at its next interest rate announcement on April 21.
On a more cautious note for the economy, Ontario, Canada‘s most populous province, initiated a four-week stay-at-home order as it battles a third wave of the COVID-19 pandemic.
Canadian government bond yields were lower across a flatter curve in sympathy with U.S. Treasuries. The 10-year fell 3.3 basis points to 1.469%.
(Reporting by Fergal Smith;Editing by Alison Williams and Jonathan Oatis)